How is Machado-Joseph Disease diagnosed?

Machado-Joseph Disease (MJD), also known as Spinocerebellar Ataxia Type 3 (SCA3), is primarily diagnosed through targeted genetic testing that identifies an abnormal expansion of CAG repeats in the ATXN3 gene. While clinical evaluation and neurological exams are essential for identifying symptoms, a definitive diagnosis of Machado-Joseph Disease requires this molecular confirmation to distinguish it from other forms of ataxia.

How is the diagnostic process for Machado-Joseph Disease structured?

The diagnostic journey for Machado-Joseph Disease often begins when a patient presents with progressive gait instability, incoordination, or oculomotor disturbances. A neurologist, specifically a movement disorder specialist, will perform a comprehensive neurological examination to assess cerebellar function, reflexes, and muscle tone. Because Machado-Joseph Disease is a rare, neurodegenerative condition, the "diagnostic odyssey" can be long and frustrating; many patients visit multiple practitioners before a specialist suspects a hereditary ataxia. Once the clinical suspicion is high, a blood draw is ordered for genetic testing to look for the specific mutation in the ATXN3 gene.

What tests and examinations are used for diagnosis?

Diagnosis relies on a combination of clinical observation and laboratory verification. Because Machado-Joseph Disease symptoms overlap with other conditions, clinicians use several tools:

• Neurological Examination: Assessing balance, coordination (ataxia), speech patterns (dysarthria), and eye movement abnormalities.


• Genetic Testing: This is the gold standard. It involves PCR or Southern blot analysis to determine the number of CAG repeats in the ATXN3 gene. Healthy individuals typically have 12–40 repeats, whereas those with Machado-Joseph Disease typically have 60–87 repeats.


• Neuroimaging: MRI scans of the brain are often performed to identify patterns of atrophy in the cerebellum, brainstem, or basal ganglia, which helps rule out structural causes of symptoms.


• Differential Diagnosis: Specialists must distinguish Machado-Joseph Disease from other spinocerebellar ataxias (like SCA1 or SCA2), Friedreich’s ataxia, Multiple System Atrophy (MSA), and Parkinson's disease.

Why is seeing a specialist essential for Machado-Joseph Disease?

We understand that the search for a diagnosis is often exhausting and isolating. Many general practitioners have never encountered a case of Machado-Joseph Disease, which can lead to misdiagnosis or delayed care. Consulting a neurologist who specializes in movement disorders or neurogenetics is crucial. These specialists are familiar with the subtle clinical features of Machado-Joseph Disease and know exactly which genetic panels to order. If you feel unheard, please know that your frustration is valid; connecting with the 42 members currently in the DiseaseMaps community can provide both emotional support and guidance on finding experienced clinicians.

Next steps

• Consult a neurologist or movement disorder specialist to review your clinical history and discuss genetic screening.


• Request a referral to a genetic counselor to discuss the implications of an ATXN3 mutation for yourself and your family members.


• Join the DiseaseMaps.org community to share experiences and learn from others living with Machado-Joseph Disease.


• Keep a symptom journal to track the progression of your symptoms, which can be invaluable for your clinical appointments.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Machado-Joseph Disease.


• Orphanet: Spinocerebellar ataxia type 3 (SCA3).


• OMIM (Online Mendelian Inheritance in Man): Spinocerebellar Ataxia 3; SCA3.


• National Ataxia Foundation: Resources and clinical guidance on hereditary ataxias.